Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
EP2611431A2 - Formulation comprising cellobiose - Google Patents
[go: Go Back, main page]

EP2611431A2 - Formulation comprising cellobiose - Google Patents

Formulation comprising cellobiose

Info

Publication number
EP2611431A2
EP2611431A2 EP11776267.4A EP11776267A EP2611431A2 EP 2611431 A2 EP2611431 A2 EP 2611431A2 EP 11776267 A EP11776267 A EP 11776267A EP 2611431 A2 EP2611431 A2 EP 2611431A2
Authority
EP
European Patent Office
Prior art keywords
cellobiose
pharmaceutical composition
composition according
average particle
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11776267.4A
Other languages
German (de)
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIMA PATENT VE LISANSLAMA HIZMETLERI LTD.STI.
Original Assignee
SIMA PATENT VE LISANSLAMA HIZMETLERI Ltd STI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMA PATENT VE LISANSLAMA HIZMETLERI Ltd STI filed Critical SIMA PATENT VE LISANSLAMA HIZMETLERI Ltd STI
Publication of EP2611431A2 publication Critical patent/EP2611431A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.
  • the patent numbered EP0464171 disclosed that the particle size of the carrier comprised in the dry powder formulation could be in the range of 5 to 1000 ⁇ . While it is possible to adjust the particle size of the carrier so as to ensure a more effective inhalation, one can also add another excipient along with the carrier.
  • the patent numbered WO8705213 relates to a dry powder formulation comprising a lubricant in addition to the carrier. Both of these patents in the prior art particularly emphasize lactose.
  • lactose is used in the products on the market such as FORADIL® and ASTMEROL®.
  • lactose is a good carrier, it leads to many problems due to its hygroscopic nature.
  • the dry powder formulation may be agglomerated and adhere to the surfaces. Since this adhesion also comprises the active agents, amount of the active agent in the formulation that reaches the patient's mouth decreases, therefore the quality of the treatment.
  • novel formulations that would be developed in order to improve the quality of the treatment and minimize the specified problems.
  • the inventor has surprisingly found that therapeutic effect is increased when long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof are carried with cellobiose.
  • cellobiose is used as carrier in the dry powder formulations of the present invention, it has been seen that the rate of agglomeration of the formulation and adhesion to the device surfaces is decreased. By this means, the amount of active agent reaching the mouth therefore the lungs of the patient increases. Thus, it provides a more effective treatment with reduced dose frequency.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising long-acting Pa- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier developed in order to be used in the treatment of respiratory diseases such as asthma and COPD.
  • the present invention provides a dry powder formulation comprising long- acting p -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose.
  • the amount of cellobiose in the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0-50 mg and preferably in the range of 3-20 mg.
  • the present invention provides a medicament in which the average particle size of cellobiose that the pharmaceutical composition comprises is in the range of 0,01 to 1000 ⁇ , preferably in the range of 5 to 500 ⁇ .
  • amount of active agent reaching the mouth and lungs of the patient is increased by adjusting the particle size of the carrier.
  • the present invention provides a pharmaceutical composition comprising cellobiose which has two different particle sizes.
  • the dry powder formulation of the present invention can comprise cellobiose which has two different particle sizes as coarse and fine in addition to the active agent.
  • the active agent can reach the lungs more easily during inhalation.
  • Fine particles adsorb onto the active areas on the coarse particles that the formulation comprises. Fine particles also have active areas. Thus, the number of active areas required for the active agent to adsorb and be carried is increased.
  • coarse particles may get caught in the upper respiratory tract. In this case, the fine particles on the active areas of the coarse particles are released with the active agents and effectively transmitted to the lungs.
  • a formulation lacks fine particles, when the coarse particles get caught in the upper respiratory tract, active agent is released there and cannot reach the lungs.
  • fine particles can fly without coarse particles and remain in the patient's mouth. Consequently, it provides advantages in the treatment that cellobiose comprised in the dry powder formulation of the present invention has two different particle sizes.
  • Average particle size of cellobiose particles comprised in the pharmaceutical composition of the present invention is smaller than 10 ⁇ , preferably smaller than 5 ⁇ and more preferably smaller than 3 ⁇ .
  • Average particle size of the coarse cellobiose particles is in the range of 10 to 1000 ⁇ , preferably in the range of 100 to 600 ⁇ and more preferably in the range of 150 to 300 ⁇ .
  • long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof in the medicament formulation comprises pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of long-acting p 2 -agonist or a combination thereof.
  • long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof comprised in the dry powder formulation can be selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof, though it is probably formoterol, arformoterol and carmoterol.
  • amount of the active agent in the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0,01 to 25 ⁇ , preferably in the range of 0,1 to 20 ⁇ and more preferably 0,5 to 15 ⁇ .
  • the present invention provides a medicament comprising long- acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof in micronized sizes.
  • Average particle size of long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof comprised in the formulation of the present invention is in the range of 0,01 to 30 ⁇ , preferably in the range of 0,05 to 10 ⁇ and more preferably in the range of 1 to 5 ⁇ . Adjustment of particle sizes is very important for medicaments administered by the inhalation route. Coarse particles can be caught in the upper respiratory tract after inhaled and this makes it harder for the particles to reach the lungs.
  • the present invention provides inhalation of the medicament comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier via dry powder inhalers.
  • the present invention provides inhalation of the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose from a capsule or blister.
  • the present invention provides administration of the dry powder formulation comprising long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose in aerosol form.
  • aerosol refers to dispersion or suspension of a liquid, solution or solid particles in air or gas.
  • the dry powder formulation can be administered in aerosol form which is characterized by containing propellant gas or not.
  • the dry powder formulation comprising cellobiose can additionally comprise other excipients.
  • excipients can be selected from a group comprising monosaccharides (glucose, etc.), disaccharides (lactose, cellobiose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xyolitol, etc.), salts (sodium chloride, calcium carbonate, etc.), inositol and/or isomers (myoinositol, etc.) or a combination thereof.
  • the pharmaceutical composition comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more active agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
  • the pharmaceutical composition comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergics such as tiotropium, ipratropium, glycopyrronium and oxytropium; p 2 -agonists such as salbutamol, fenoterol, terbutaline, carbuterol and pirbuterol; corticosteroids such as beclomethasone, budesonide, ciclesonide, fluticasone and mometasone; xanthines such as doxyphyllin, theobromine, theophylline and aminophylline; antileukotrienes such as montelukast, pranlucast, zafirlukast, ritolukast, sulukast, tomelukast, verlukast, iralukas
  • the pharmaceutical composition comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • these respiratory diseases can be, but not limited to, asthma at any stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis.
  • This treatment can be prophylactic or symptomatic.
  • the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.

Description

FORMULATION COMPRISING CELLOBIOSE
Purpose of the Invention:
The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.
Background of the Invention:
Administration of the drugs by the inhalation route has an important place in the treatment of respiratory tract diseases such as asthma and COPD since the drugs given by the inhalation route directly reach the lungs and start their activity there. Active agents are used in pretty little amounts as they directly reach the target area. To this respect, both for production of the formulation and its administration in effective doses, one or more excipients are required in addition to the active agent. Formulation is diluted and carried with the excipients. According to this, formulations comprise excipients more than active agents.
To enable effective inhalation of dry powder formulations, there have been many studies conducted in the prior art in order to select the excipient and adjust the features of the excipient selected such as particle size, percentage by weight. The patent numbered EP0464171 disclosed that the particle size of the carrier comprised in the dry powder formulation could be in the range of 5 to 1000 μιη. While it is possible to adjust the particle size of the carrier so as to ensure a more effective inhalation, one can also add another excipient along with the carrier. The patent numbered WO8705213 relates to a dry powder formulation comprising a lubricant in addition to the carrier. Both of these patents in the prior art particularly emphasize lactose. Furthermore, it is also seen that lactose is used in the products on the market such as FORADIL® and ASTMEROL®. However, although lactose is a good carrier, it leads to many problems due to its hygroscopic nature. With hygroscopic lactose, the dry powder formulation may be agglomerated and adhere to the surfaces. Since this adhesion also comprises the active agents, amount of the active agent in the formulation that reaches the patient's mouth decreases, therefore the quality of the treatment. Today, there is still need for novel formulations that would be developed in order to improve the quality of the treatment and minimize the specified problems. Moreover, there is still need for a simple, more effective treatment with reduced dose frequency. Detailed Explanation of the Invention:
The inventor has surprisingly found that therapeutic effect is increased when long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof are carried with cellobiose. In the case that cellobiose is used as carrier in the dry powder formulations of the present invention, it has been seen that the rate of agglomeration of the formulation and adhesion to the device surfaces is decreased. By this means, the amount of active agent reaching the mouth therefore the lungs of the patient increases. Thus, it provides a more effective treatment with reduced dose frequency.
The present invention provides a pharmaceutical composition comprising long-acting Pa- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier developed in order to be used in the treatment of respiratory diseases such as asthma and COPD.
In another aspect, the present invention provides a dry powder formulation comprising long- acting p -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose.
According to the present invention, the amount of cellobiose in the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0-50 mg and preferably in the range of 3-20 mg.
In another aspect, the present invention provides a medicament in which the average particle size of cellobiose that the pharmaceutical composition comprises is in the range of 0,01 to 1000 μπι, preferably in the range of 5 to 500 μηι. In the present invention, amount of active agent reaching the mouth and lungs of the patient is increased by adjusting the particle size of the carrier.
In another aspect, the present invention provides a pharmaceutical composition comprising cellobiose which has two different particle sizes. The dry powder formulation of the present invention can comprise cellobiose which has two different particle sizes as coarse and fine in addition to the active agent. Thus, the active agent can reach the lungs more easily during inhalation. Fine particles adsorb onto the active areas on the coarse particles that the formulation comprises. Fine particles also have active areas. Thus, the number of active areas required for the active agent to adsorb and be carried is increased. In another aspect, coarse particles may get caught in the upper respiratory tract. In this case, the fine particles on the active areas of the coarse particles are released with the active agents and effectively transmitted to the lungs. If a formulation lacks fine particles, when the coarse particles get caught in the upper respiratory tract, active agent is released there and cannot reach the lungs. In another aspect, fine particles can fly without coarse particles and remain in the patient's mouth. Consequently, it provides advantages in the treatment that cellobiose comprised in the dry powder formulation of the present invention has two different particle sizes.
Average particle size of cellobiose particles comprised in the pharmaceutical composition of the present invention is smaller than 10 μιη, preferably smaller than 5 μηι and more preferably smaller than 3 μηι. Average particle size of the coarse cellobiose particles, on the other hand, is in the range of 10 to 1000 μπι, preferably in the range of 100 to 600 μιη and more preferably in the range of 150 to 300 μπι.
According to the present invention, long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof in the medicament formulation comprises pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of long-acting p2-agonist or a combination thereof.
According to the present invention, long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof comprised in the dry powder formulation can be selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof, though it is probably formoterol, arformoterol and carmoterol.
According to the present invention, amount of the active agent in the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0,01 to 25 μηι, preferably in the range of 0,1 to 20 μιτι and more preferably 0,5 to 15 μπι.
According to another aspect, the present invention provides a medicament comprising long- acting 2-agonist and/or pharmaceutically acceptable derivatives thereof in micronized sizes. Average particle size of long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof comprised in the formulation of the present invention is in the range of 0,01 to 30 μπι, preferably in the range of 0,05 to 10 μπι and more preferably in the range of 1 to 5 μπι. Adjustment of particle sizes is very important for medicaments administered by the inhalation route. Coarse particles can be caught in the upper respiratory tract after inhaled and this makes it harder for the particles to reach the lungs.
The present invention provides inhalation of the medicament comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier via dry powder inhalers.
In another aspect, the present invention provides inhalation of the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose from a capsule or blister.
In another aspect, the present invention provides administration of the dry powder formulation comprising long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose in aerosol form. The term "aerosol" refers to dispersion or suspension of a liquid, solution or solid particles in air or gas. According to this, the dry powder formulation can be administered in aerosol form which is characterized by containing propellant gas or not.
According to the present invention, the dry powder formulation comprising cellobiose can additionally comprise other excipients. These excipients can be selected from a group comprising monosaccharides (glucose, etc.), disaccharides (lactose, cellobiose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xyolitol, etc.), salts (sodium chloride, calcium carbonate, etc.), inositol and/or isomers (myoinositol, etc.) or a combination thereof.
According to the present invention, the pharmaceutical composition comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more active agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
According to the present invention, the pharmaceutical composition comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergics such as tiotropium, ipratropium, glycopyrronium and oxytropium; p2-agonists such as salbutamol, fenoterol, terbutaline, carbuterol and pirbuterol; corticosteroids such as beclomethasone, budesonide, ciclesonide, fluticasone and mometasone; xanthines such as doxyphyllin, theobromine, theophylline and aminophylline; antileukotrienes such as montelukast, pranlucast, zafirlukast, ritolukast, sulukast, tomelukast, verlukast, iralukast, ablukast and cinalukast; PDEIV inhibitors such as roflumilast, piclamilast and cilomilast; antihistamines such as levocetirizine, desloratadin, fexofenadine, vapitadine and alcaftadine.
The pharmaceutical composition comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). Accordingly, these respiratory diseases can be, but not limited to, asthma at any stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis. This treatment can be prophylactic or symptomatic. In addition, the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.

Claims

Claims:
1. A pharmaceutical composition comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier.
2. The pharmaceutical composition according to claim 1 characterized in that the amount of cellobiose comprised in said composition is in the range of 0-50 mg.
3. The pharmaceutical composition according to claim 2 characterized in that the amount of cellobiose comprised in said composition is in the range of 3-20 mg.
4. The pharmaceutical composition according to claim 1 characterized in that the average particle size of cellobiose comprised in said composition is in the range 0,01 to 1000 μηι.
5. The pharmaceutical composition according to claim 1 characterized in that cellobiose comprised in said composition has two different average particle sizes.
6. The pharmaceutical composition according to claim 5 characterized in that the average particle size of fine cellobiose particles is smaller 10 μηι.
7. The pharmaceutical composition according to claim 6 characterized in that the average particle size of fine cellobiose particles is smaller 5 μπι.
8. The pharmaceutical composition according to claim 7 characterized in that the average particle size of fine cellobiose particles is smaller 3 μπι.
9. The pharmaceutical composition according to claim 5 characterized in that the average particle size of coarse cellobiose particles is in the range of 10 to 1000 μπι.
10. The pharmaceutical composition according to claim 9 characterized in that the average particle size of coarse cellobiose particles is in the range of 100 to 600 μπι.
11. The pharmaceutical composition according to claim 10 characterized in that the average particle size of coarse cellobiose particles is in the range of 150 to 300 μιη.
12. The pharmaceutical composition according to claim 1 characterized in that long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof.
13. The pharmaceutical composition according to claim 12 characterized in that long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof is selected from a group comprising formoterol, carmoterol or a combination thereof.
14. The pharmaceutical composition according to claim 1 characterized in that said compositions additionally comprises one or more agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
EP11776267.4A 2010-09-01 2011-08-24 Formulation comprising cellobiose Withdrawn EP2611431A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07250A TR201007250A2 (en) 2010-09-01 2010-09-01 Formulation containing cellobiose.
PCT/TR2011/000198 WO2012030308A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Publications (1)

Publication Number Publication Date
EP2611431A2 true EP2611431A2 (en) 2013-07-10

Family

ID=44883366

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11776267.4A Withdrawn EP2611431A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Country Status (3)

Country Link
EP (1) EP2611431A2 (en)
TR (1) TR201007250A2 (en)
WO (1) WO2012030308A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
EA201590019A1 (en) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. DRY POWDER INHALERS, CARRIER CONTAINING, EXCELLENT FROM LACTOSE
EP3247403A1 (en) 2015-01-22 2017-11-29 Pfeifer & Langen GmbH & Co. KG Cellobiose in compositions for consumption or ingestion
IT201900008340A1 (en) * 2019-06-07 2020-12-07 Genetic S P A MONTELUKAST SALTS AND THEIR PHARMACEUTICAL COMPOSITIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012030308A2 *

Also Published As

Publication number Publication date
WO2012030308A3 (en) 2012-08-09
TR201007250A2 (en) 2012-03-21
WO2012030308A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
TWI565481B (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
EP2575786B1 (en) Process for dry powder formulations
IL143986A (en) Combinations of formoterol and a tiotropium salt
MX2013001172A (en) Dry powder formulation comprising a phosphodiesterase inhibitor.
JP2014516062A (en) Combinations containing umecridinium and corticosteroids
CA2948553A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd
EP2682102A2 (en) Inhalation Compositions Comprising Corticosteroid and Sorbitol
EP2563364A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
EP2682098A2 (en) Inhalation Compositions
EP2611431A2 (en) Formulation comprising cellobiose
US20100210611A1 (en) Combination therapy
WO2013009271A1 (en) New improved dry powder formulation
WO2012166070A1 (en) Dry powder formulation with improved flow characteristics
JP7712916B2 (en) Novel carrier particles for dry powder formulations for inhalation
EP2611447A2 (en) Formulation of comprising tiotropium and a calcium channel blocker
WO2011136752A1 (en) Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
TR2023012447A1 (en) LIQUID PHARMACEUTICAL COMPOSITIONS WITHOUT PROPELLANT GAS
TR2023014905A1 (en) AEROSOL COMPOSITIONS CONTAINING STEROIDS
TW201618759A (en) Dry powder for inhalation formulation having improved stability of combined active ingredients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121231

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIMA PATENT VE LISANSLAMA HIZMETLERI LTD.STI.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIMA PATENT VE LISANSLAMA HIZMETLERI LTD.STI.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141209